Metformin Stabilizes the Abdominal Aorta in Aneurysm by Restoring VSMC Mitochondrial Homeostasis via the AMPK-SIRT1-PGC-1α Axis

This study demonstrates that metformin prevents abdominal aortic aneurysm progression by activating the AMPK-SIRT1-PGC-1α axis to restore vascular smooth muscle cell mitochondrial homeostasis and suppress senescence, a protective mechanism that is entirely dependent on PGC-1α.

The Gist

The Big Picture: A "Leaky Hose" Problem

Imagine your body's main artery (the aorta) is like a giant, high-pressure garden hose. Over time, due to stress, smoking, or high blood pressure, a weak spot can form in the hose. This weak spot starts to bulge out, forming a balloon-like swelling called an Abdominal Aortic Aneurysm (AAA).

This is a ticking time bomb. If it bursts, it's almost always fatal. Currently, doctors can only watch it grow or perform risky surgery to replace the hose. There is no pill to stop it from getting bigger.

However, doctors noticed something strange: People who take Metformin (a common, cheap diabetes drug) seem to have fewer aneurysms, and if they do have them, they grow slower. Scientists wanted to know: How does a diabetes drug fix a broken artery?

The Cast of Characters

To understand the answer, we need to meet the "workers" inside your artery walls:

1. VSMCs (Vascular Smooth Muscle Cells): Think of these as the concrete workers building and maintaining the artery wall. When they are healthy, they are strong, contractile, and hold the wall tight.
2. Mitochondria: These are the batteries inside the concrete workers. They provide the energy needed to do their job.
3. PGC-1α: This is the Chief Engineer of the batteries. When the Chief Engineer is working, the batteries stay charged and healthy.
4. Metformin: The Superhero Medic that steps in to save the day.

The Problem: The Batteries Die, The Workers Quit

In a diseased artery, the "Chief Engineer" (PGC-1α) gets fired or goes on strike.

• The Result: The batteries (mitochondria) inside the concrete workers (VSMCs) start to break down. They leak toxic waste (ROS) and run out of power (ATP).
• The Consequence: The exhausted workers stop being strong "concrete." They get tired, old, and senescent. They stop holding the wall tight and start acting like chaotic construction crews, tearing down the wall and spewing out inflammatory chemicals. This causes the artery to bulge and eventually rupture.

The Discovery: How Metformin Saves the Day

The researchers found that Metformin acts like a power surge that re-hires the Chief Engineer.

1. The Chain Reaction: Metformin wakes up two other managers, AMPK and SIRT1.
2. The Rescue: These two managers team up to bring the Chief Engineer (PGC-1α) back to work.
3. The Fix: Once the Chief Engineer is back, the batteries get repaired. The toxic waste is cleaned up, and the energy returns.
4. The Outcome: The concrete workers (VSMCs) stop acting old and chaotic. They remember how to be strong, contractile, and protective. The artery wall stabilizes, and the bulge stops growing.

The "Smoking Gun" Experiment

To prove this was really happening, the scientists did a clever trick. They created mice where they removed the Chief Engineer (PGC-1α) specifically from the artery workers.

• What happened? The mice got aneurysms very fast.
• The Test: They gave these mice Metformin.
• The Result: Nothing. The drug didn't work.

This proved that Metformin needs the Chief Engineer (PGC-1α) to do its job. Without him, the drug is useless. It's like trying to fix a car with a flat tire using a wrench when the car has no engine; the tool is great, but the engine is missing.

The Conclusion: A New Hope

This paper tells us that Metformin isn't just lowering blood sugar; it's acting as a battery repair kit for your arteries.

• The Mechanism: Metformin → Turns on AMPK/SIRT1 → Wakes up PGC-1α → Fixes the batteries → Stops the artery workers from aging and quitting.
• The Takeaway: This gives scientists a new reason to potentially use Metformin (or drugs that target this specific pathway) to stop aneurysms before they burst. It turns a "diabetes drug" into a potential "life-saving artery stabilizer."

In short: The artery was breaking because its workers were running out of power. Metformin fixed the power plant, the workers got their strength back, and the artery stopped bulging.

Technical Summary

1. Problem Statement

Abdominal Aortic Aneurysm (AAA) is a life-threatening degenerative vascular disease with a rupture mortality rate of 80–90%. Currently, there are no approved pharmacological therapies to halt AAA progression; management is limited to surveillance and surgical repair.

• Clinical Observation: Epidemiological data suggests that patients with Type 2 Diabetes Mellitus (T2DM) taking metformin have a lower incidence and slower progression of AAA.
• Knowledge Gap: The mechanism behind metformin's protective effect is unknown. While PGC-1α (a master regulator of mitochondrial biogenesis) is known to be downregulated in AAA tissues, its specific role in metformin-mediated protection and its relationship with Vascular Smooth Muscle Cell (VSMC) senescence and phenotypic switching has not been elucidated.

2. Methodology

The study employed a multi-faceted approach combining in vivo animal models, in vitro cell models, genetic manipulation, and pharmacological inhibition.

• Animal Models:
  • AAA Induction: Porcine Pancreatic Elastase (PPE) was applied externally to the infrarenal abdominal aorta of male C57BL/6J mice.
  • Genetic Models: Generation of VSMC-specific Ppargc1a knockout mice (Ppargc1a^VSMC-KO) using Itga8-CreERT2 crossed with Ppargc1a^flox/flox mice. Lineage tracing was confirmed using Rosa26^mTmG reporter mice.
  • Treatment Groups: Mice received metformin (50 mg/kg/day, oral gavage) or vehicle. Some groups received pharmacological inhibitors: Compound C (AMPK inhibitor) and Ex-527 (SIRT1 inhibitor).
• Cell Models:
  • Primary VSMCs were isolated from wild-type and Ppargc1a^VSMC-KO mice.
  • Senescence Induction: Cells were treated with Angiotensin II (Ang II) to induce senescence, with or without metformin co-treatment.
• Techniques:
  • Imaging: High-frequency ultrasound for aneurysm diameter monitoring; Transmission Electron Microscopy (TEM) for mitochondrial ultrastructure.
  • Molecular Analysis: Western Blot, qPCR, Immunofluorescence (IF), and SA-β-gal staining for senescence markers.
  • Omics: Whole transcriptome sequencing (RNA-seq) of AAA tissues and re-analysis of public single-cell RNA-seq data (GSE152583) to identify cellular sources of PGC-1α.
  • Functional Assays: CCK-8 (viability), CCK-8 migration, ATP assays, and ROS measurement.

3. Key Contributions

1. Mechanistic Elucidation: The study defines a novel signaling axis: Metformin → AMPK/SIRT1 → PGC-1α → Mitochondrial Homeostasis → VSMC Stability.
2. Genetic Validation: It provides the first direct genetic evidence that VSMC-intrinsic PGC-1α is non-redundant and essential for metformin's protective effects against AAA.
3. Phenotypic Insight: It links mitochondrial dysfunction directly to VSMC senescence and the pathological switch from a contractile to a synthetic/inflammatory phenotype.
4. Therapeutic Repurposing: It offers a strong mechanistic rationale for repurposing metformin as a non-surgical therapy for AAA.

4. Key Results

A. Metformin Attenuates AAA and Restores PGC-1α

• In Vivo: Metformin treatment significantly reduced aneurysm expansion in PPE-induced mice. It suppressed senescence markers (p53, p21) and inflammatory cytokines (IL-6, TNF-α) while restoring the contractile marker Smoothelin (SMTN).
• PGC-1α Restoration: Metformin treatment significantly upregulated PGC-1α protein and mRNA levels in AAA tissues. Single-cell analysis confirmed that PGC-1α is predominantly expressed in VSMCs.

B. VSMC-Specific PGC-1α Deficiency Abrogates Protection

• Knockout Phenotype: Ppargc1a^VSMC-KO mice exhibited accelerated aneurysm growth, severe mitochondrial fragmentation, ATP depletion, and ROS accumulation.
• Loss of Efficacy: Crucially, metformin failed to protect Ppargc1a^VSMC-KO mice. The drug could not suppress aneurysm expansion, senescence, or inflammation in the absence of VSMC PGC-1α, proving PGC-1α is the critical downstream mediator.

C. Mitochondrial Homeostasis is Central

• Ultrastructure: TEM revealed that Ang II induced mitochondrial swelling and cristae disorganization. Metformin rescued these defects in wild-type cells but failed to do so in PGC-1α deficient cells.
• Bioenergetics: Metformin restored ATP levels and reduced ROS in control VSMCs but had no effect in PGC-1α deficient VSMCs.

D. The AMPK–SIRT1–PGC-1α Axis

• Signaling Pathway: Metformin activated AMPK (p-AMPK) and SIRT1, leading to PGC-1α upregulation.
• Inhibition Studies: Pharmacological inhibition of AMPK (Compound C) or SIRT1 (Ex-527) blocked metformin-induced PGC-1α upregulation. Consequently, the protective effects of metformin on aneurysm size, senescence, and mitochondrial function were completely abolished.
• Bidirectional Regulation: The study suggests a positive feedback loop where PGC-1α deficiency also reduces SIRT1 levels, further destabilizing the system.

5. Significance and Conclusion

This study establishes PGC-1α as a "cell-autonomous guardian" of vascular health. It demonstrates that metformin does not merely lower blood glucose but acts via a glycemia-independent mechanism to stabilize the aortic wall.

• Pathophysiological Insight: AAA progression is driven by a feed-forward loop where stress reduces PGC-1α, leading to mitochondrial failure, VSMC senescence, and phenotypic switching.
• Clinical Implication: The findings provide a robust mechanistic foundation for repurposing metformin for AAA treatment. Furthermore, they identify the AMPK–SIRT1–PGC-1α axis as a promising therapeutic target for developing new drugs (e.g., SIRT1 activators or NAD+ boosters) to prevent aortic rupture in patients who are not candidates for surgery.

Conclusion: Metformin restrains AAA by restoring VSMC mitochondrial homeostasis via the AMPK/SIRT1→PGC-1α axis, positioning PGC-1α as a critical, non-redundant target for vascular degeneration therapy.